ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome

Permanent link
https://hdl.handle.net/10037/8996
DOI
https://doi.org/10.1016/j.clim.2015.05.018
Thumbnail
View/Open
article.pdf (660.3Kb)
(PDF)
Date
2015-06-23
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Volokhina, Elena B.; van de Kar, Nicole C.A.J.; Bergseth, Grethe; van der Velden, Thea J.A.M.; Westra, Dineke; Wetzels, Jack F.M.; van den Heuvel, Lambertus P.; Mollnes, Tom Eirik
Abstract
Complement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but associated with high costs. Complement inhibition monitoring in these patients has not been standardized. In this study we evaluated novel functional assays for application in routine follow-up. We documented that the Wieslab® complement screen assay showed a sensitivity of 1–2% of C5 activity by adding purified C5 or normal human serum to a C5 deficient serum. All the patient samples obtained during the treatment course, were completely blocked for terminal complement pathway activity for up to four weeks after the eculizumab infusion. Levels of complexes between eculizumab and C5 were inversely correlated to the complement activity (p = 0.01). Moreover, titrating serum from eculizumab-treated patients into normal serum revealed that eculizumab was present in excess up to four weeks after infusion. Thus, we demonstrate sensitive, reliable and easy-performed assays which can be used to design individual eculizumab dosage regimens.
Description
Published version also available at http://dx.doi.org/10.1016/j.clim.2015.05.018
Publisher
Elsevier
Citation
Clinical Immunology 2015, 160(2):237-243
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)